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Synovial Regulatory T Cells Occupy a Discrete TCR Niche in
Human Arthritis and Require Local Signals To Stabilize
FOXP3 Protein Expression
David Bending, Eirini Giannakopoulou,1 Hannah Lom, and Lucy R. Wedderburn
Although there is great interest in harnessing the immunosuppressive potential of FOXP3+ regulatory T cells (Tregs) for treating
autoimmunity, a sizeable knowledge gap exists regarding Treg fate in human disease. In juvenile idiopathic arthritis (JIA)
patients, we have previously reported that atypical CD25+FOXP32 Treg-like cells uniquely populate the inflamed site. Intrigu-
ingly, their proportions relative to CD25+FOXP3+ Tregs associate with arthritis course, suggesting a role in disease. The ontogeny
of these FOXP32 Treg-like cells is, however, unknown. In this study, we interrogated clonal relationships between CD4+ T cell
subsets in JIA, using high-throughput TCR repertoire analysis. We reveal that FOXP3+ Tregs possess highly exclusive TCRb
usage from conventional T cells, in blood, and also at the inflamed site, where they are clonally expanded. Intriguingly, the
repertoires of FOXP3+ Tregs in synovial fluid are highly overlapping with CD25+FOXP32 Treg-like cells, indicating fluctuations
in FOXP3 expression in the inflamed joint. Furthermore, cultured synovial Tregs rapidly downregulated FOXP3 protein (but not
mRNA), and this process was prevented by addition of synovial fluid from JIA patients, through an IL-6–independent mechanism.
Our findings suggest that most Tregs arise from a separate lineage from conventional T cells, and that this repertoire divergence is
largely maintained under chronic inflammatory conditions. We propose that subsequent Treg expansions at the inflamed site
creates an environment that leads to competition for limited resources within the synovium, resulting in the destabilization of
FOXP3 expression in some Tregs. The Journal of Immunology, 2015, 195: 5616–5624.
F
orkhead box protein 3+ regulatory T cells (Tregs) are
thought to be critical for the maintenance of tolerance
(1–3) and the control of excessive inflammation, yet Tregs
are frequently increased in numbers in autoimmune arthritis of
childhood, juvenile idiopathic arthritis (JIA) (4, 5). JIA has served
as a unique and useful human model to understand Treg dynamics
and interactions for several reasons: 1) access to the anatomical
site of disease gives precious insight into the mechanisms involved
in the perpetuation of chronic inflammation in humans; and 2)
patients with JIA can have diverging clinical outcomes, allowing
correlation between immunological findings and disease prognosis.
Two striking findings from recent research have demonstrated that
both an increased frequency of FOXP3+ Tregs (4, 5) and coexpression
of CD25 and FOXP3 (6) are associated with the milder disease
courses in JIA. These data strongly suggest that treatment strategies to
boost/augment Treg numbers could be fruitful for treating JIA, or
indeed other autoimmune conditions. However, studies of Tregs often
consider the phenotype and function of the Treg population as one
homogenous group, negating the fact that Tregs likely express a di-
verse repertoire of TCRs, signals through which are essential to their
function (7). TCR diversity is driven in part because of genetic re-
combination of Variable, Diversity and Junctional gene segments (8)
within the TCRB gene family locus. This recombination generates a
unique DNA sequence that can be used as a barcode to track the fates
of T cell clones during immune responses.
The huge diversity of the TCR repertoire has previously been a
barrier to meaningful analysis in human disease; however, recent
technological advances mean high-throughput repertoire analysis
is feasible and cost-effective. Recent exhaustive repertoire se-
quencing of human peripheral blood suggests a highly diverse
repertoire with a lower bound limit of at least a million unique
clonotypes (9). However, the repertoires involved in human ar-
thritis are predicted to be more clonal, based on heteroduplex TCR
analysis in isolated CD4/CD8 T cells (10). TCR repertoires are
likely to be important in autoimmunity because it has been shown
in JIA that T cell clonotype expansions mirror the HLA class I
(CD8 expanded) or class II (CD4 expanded) association of ar-
thritis (10). In addition, recent insight in animal models of arthritis
suggests that certain TCRs can transfer arthritis even in the pres-
ence of Tregs (11). Furthermore, repertoire analysis has started
to yield unprecedented insight into the heterogeneity of human
memory Th cells that respond to common pathogens or vaccines
(12), giving us a greatly enhanced picture of developmental re-
lationships between CD4+ T cell subsets.
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Several observations in JIA have questioned both the develop-
mental relationships between Tregs and conventional T cells (Tcons)
and the relationships between different Treg subsets at the inflamed
site. We have previously reported that Tregs and pathogenic Tcons
show an inverse reciprocal relationship at the inflamed site in JIA (5).
This could imply a developmental relationship between these two
subsets, which could be easily determined only through analysis of
TCR repertoires. Analysis in mice has suggested that the repertoires
of Tregs and Tcons are diverse, with only a partial overlap in the
periphery (13–15). The relationship in humans remains to be de-
termined. Second, we also reported that Tregs can adopt atypical
phenotypes at the inflamed site: in addition to “classic” CD25+
FOXP3+ Tregs, CD252FOXP3+ and CD25+FOXP32 Treg-like
populations exist, both of which display demethylation at the Treg-
specific demethylated region (TSDR) (6). The origin of these pop-
ulations is unclear, but we have reported that Treg coexpression of
CD25 and FOXP3 is important for disease progression (6), which
means understanding Treg fate and provenance at inflamed sites is
important for understanding disease.
In this study, we aimed to determine the clonal relationships
between Tcon and Treg subsets both in blood and in the inflamed
site of JIA patients, using the immunoSEQ TCRB survey platform
(16, 17). Our results demonstrate a near-complete separation of
Tregs from Tcon TCR repertoires in both blood and the inflamed
site in JIA. Synovial T cell repertoires contain numerous expanded
clones; however, synovial Tregs cluster more closely with blood
Tregs than Tcons from the inflamed site, implying that a signifi-
cant proportion of Tregs in the joint arise from Tregs in the blood.
Intriguingly, the repertoires of FOXP3+ Tregs in synovial fluid
(SF) are highly overlapping with atypical CD25+FOXP32 Treg-
like cells, implying dynamic FOXP3 expression in vivo. This is
illustrated by the finding that FOXP3hi Tregs rapidly downregulate
FOXP3 protein in the absence of SF, highlighting that local signals
are essential for sustaining FOXP3 expression. Our findings give
unprecedented insight into the makeup of the TCR repertoires
involved in a human autoimmune response, as well as the dynamic
relationships between Tcon and Treg subsets in vivo.
Materials and Methods
Human samples
Twenty-five patients with JIA contributed SF mononuclear cells (SFMCs;
see Supplemental Table I) or PBMCs, and 60 patients contributed SF to
this study. All fulfilled the International League of Associations for
Rheumatology classification criteria (18). Nine healthy control volunteers
donated PBMCs, all with no known autoimmune or genetic conditions.
Written informed consent was received from all human participants before
inclusion in the study, with informed parental consent where appropriate.
The study had full ethical approval from the local research ethic committee
(95RU04). SFMCs and PBMCs were prepared by density gradient cen-
trifugation using Lymphoprep (Axis-Shield) with SF samples undergoing
pretreatment with hyaluronidase (10 U/ml; Sigma). Samples were cryo-
preserved until use. SF pools were made from 10 to 15 JIA individuals
and treated for 30 min with 10 U/ml hyaluronidase before aliquoting and
freezing at 280˚C. SF was added to cultures at the specified percentage of
the final well volume.
Abs and reagents
The following directly conjugated Abs were used in flow cytometry: BV711 or
FITC-conjugated CD4 [OKT4 (Biolegend) or RPA-T4 (eBioscience)], BV711-
(clone A019D5; Biolegend) or FITC-conjugated CD127 (eBioRDR5; eBio-
science), PE- (BD Biosciences) or BV421-conjugated (Biolegend) CD25
(MA251), allophycocyanin-conjugated FOXP3 (236A/E7; eBioscience) or
PE-Cy7–conjugated FOXP3 (PCH101; eBioscience), V450-conjugated active
CASPASE3 (C92-605; BD Biosciences), PE-conjugated p-(Y705)STAT3
(4/P-STAT3; BD Biosciences), PE-conjugated p-(Y694)STAT5 (47/STAT5;
BD Biosciences), PE-conjugated CTLA-4 (14D3; eBioscience). Recombinant
human IL (rhIL)-2 (Roche), IL-6, rhIL-7, rhIL-15 (Peprotech), and rhIL-6
(BD Biosciences) were used at the concentrations indicated in the figure
legends. Tocilizumab (TOC; anti–IL-6R) and infliximab (anti–TNF-a)
were used at a final concentration of 10 mg/ml. Cycloheximide (Sigma)
was used at a concentration of 50 mg/ml.
Flow cytometry
Flow cytometry was performed with directly conjugated Abs as previously
described (6). A fixable Blue LIVE/DEAD dye (Life Technologies) was
used to exclude dead cells from analysis. FOXP3 and CTLA-4 (total)
staining was performed using the eBioscience FOXP3 staining buffers. For
staining of phosphorylated proteins, BD Fix Buffer I and BD Phosflow
perm buffer III were used according to manufacturer’s instructions. In
brief, sorted Tregs (at 5 3 105/ml in 100 ml RPMI 1640) were incubated
for 15 min with either SF or 10 ng/ml rhIL-6 before addition of 100 ml BD
Fix Buffer I and incubated for 10 min at 37˚C. Cells were washed ex-
tensively in PBS, then permeabilized by addition of 1 ml ice-cold Perm Buffer
III and incubation for 30 min on ice. Cells were washed three times and then
stained for PE–anti–p-STAT3 or PE–anti–p-STAT5. Data were collected on
the LSR II, FACS Aria, or FACSCalibur flow cytometers (all BD Biosciences).
Flow cytometry data were analyzed using FloJo (Tree Star) software.
Cell sorting
For live cell sorting, cells were pre-enriched for CD4+ T cells using a
negative selection enrichment kit (STEMCELL Technologies). Cells were
stained for CD4, CD25, and CD127, before filtering and adding DAPI or
propidium iodide (PI). Cells were sorted on a FACS Aria (BD Biosciences)
cell sorter as follows: Treg: CD4+CD127loCD252DAPI/PI2; Tcon: CD4+
CD127hiCD25loDAPI/PI2. Sorting of fixed and FOXP3-stained cells was
performed as previously described (6), with the following modification:
cells were collected into a PBS solution containing 10 mM HEPES
(Sigma).
DNA, RNA extraction, and quantitative PCR
DNA was extracted using a modified phenol protocol as previously de-
scribed (6). RNAwas extracted using the PicoPure kit (Life Technologies).
Typically, 2.5 3 104 sorted cells or cultured cells were washed once with
PBS and then once with PBS containing 50 mM EDTA (Sigma) before
lysing in the RNA extraction buffer and incubating at 42˚C for 30 min,
before centrifugation of the lysate and freezing. RNA was extracted
according to the manufacturer’s instructions and converted to cDNA using
random hexamer primers as previously described (6). cDNAwas amplified
using SYBR Green Mastermix (Bio-Rad) with primers to GAPDH (Qiagen),
ACTB (For: 59-AGATGA CCC AGATCATGT TTG AG-39; Rev: 59-AGG
TCC AGA CGC AGG ATG-39), or FOXP3 (primer sequences For: 59-ACC
TGG AAG AAC GCC ATC-39; Rev: 59-TGT TCG TCC ATC CTC CTT TC-
39) on the Rotor-gene 6000 Corbert thermocycler (Qiagen) using the fol-
lowing cycling conditions: 95˚C 5 min, then 40 cycles of 95˚C 30 s, 60˚C
30 s, 72˚C 30 s. SYBR green emission data and melt curves were collected.
FOXP3 gene expression is displayed relative to GAPDH or ACTB using
the 22DCt method.
TCRB sequencing and analysis
A total of 100–400 ng genomic DNA from sorted T cell subsets was
processed by Adaptive Biotechnologies (Seattle, WA) on the immunoSEQ
human TCRB survey platform (16, 17). In brief, input DNAwas amplified
in a two-step multiplex PCR in which the first PCR amplified the CDR3
region of T cell genomes and the second PCR added adaptor sequences
compatible with Illumina Next Generation Sequencing (NGS) platform.
Sequencing was performed using Illumina’s Next Generation Sequencing
platform. Using a baseline developed from a suite of synthetic templates,
we used primer concentrations and computational corrections to correct for
the primer bias common to multiplex PCRs. Raw sequence data were
filtered based on the TCRb V, D, and J gene definitions provided by the
IMGT (ImMunoGeneTics) database (http://www.imgt.org) and binned
using a modified nearest-neighbor algorithm to merge closely related se-
quences and remove both PCR and sequencing errors. Data were analyzed
using the Adaptive Biotechnologies immunoSEQ Analyzer. Analysis was
based on unique, productive reads at the nucleotide level. The degree of
repertoire clonality was defined as the reciprocal of normalized entropy
[entropy was calculated by the Shannon entropy index (19)] and then
normalized by dividing the entropy score by the log (2) of the unique
productive reads, thereby allowing comparison of samples that vary by the
total number of reads detected. The repertoire overlap between two sam-
ples (A and B) was calculated using the immunoSEQ analyzer. The
overlap statistic is simply the percent of shared sequences for all pairwise
comparisons. That is, the sum of shared sequences for sample A and
sample B, divided by the sum of sequences for sample A and sample B.
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Cell culture
Cells were cultured on 96-well V-bottom plates (CoStar) in 10% FBS RPMI
1640 at 37˚C 5% CO2. Cells were cultured at a final concentration of 5 3
105/ml for the time points indicated. For SF and JIA peripheral blood (PB)
Tregs, 2.5 3 104 cells were cultured in 50 ml. For control Treg, 2.5 3 104
(Fig. 3, Supplemental Fig. 2) or 5 3 104 (Fig. 6) cells were used. In some
experiments, cultures were supplemented with 10 or 50% SF, recombinant
cytokines (IL-2, IL-7, IL-15), or cytokine blocking Abs (anti-IL-6R or
anti-TNFa) as stated in the figure legends.
Luminex
Sixty SFs from JIA patients were analyzed for IL-6 and IL-10 expression
levels using cytokine multiplex assay as previously described (20).
Statistics
Statistical analysis was performed on Prism 5 for Mac (GraphPad) software.
For clarity, statistical tests and error bar descriptions are included in the
figure legends. A p value ,0.05 was deemed statistically significant.
Results
The TCR repertoires of Tregs and Tcons show high exclusivity
in blood and SF of JIA patients
We decided to use the immunoSEQ platform (Adaptive Biotech-
nologies) (16, 17) to perform high-throughput TCR repertoire
analysis of CD4+ T cell subsets in JIA patients (Fig. 1), because
this platform can use genomic DNA as a template and has been
successfully used by other groups to address TCR repertoires in
health and disease (12, 21). A total of 100,000–200,000 Tregs and
Tcons were isolated from the blood and SF of the same patients,
based on cell-surface expression of CD25 and CD127 (Tregs:
CD4+CD127loCD25hi, Tcons: CD4+CD127hiCD25lo; Fig. 1A),
to high purity. Genomic DNA was extracted and run on the
immunoSEQ TCRB survey platform. TCR repertoires at the in-
flamed site were significantly more clonal compared with the pe-
ripheral blood, as expected (Fig. 1B). In keeping with this, the
inflamed site contained numerous expanded clones, with the most
abundant clones being ∼1–2% in the SF, compared with 0.1% in
the blood compartment (Fig. 1B). We next compared the sharing
of nucleotide sequences, which would indicate clonal sharing
among different repertoires (Fig. 1C, Supplemental Fig. 1). Almost
no sharing of clones was detected between blood Tregs and blood
Tcons or SF Tcons. Similarly, blood and SF Tcon repertoires also
shared very few sequences. Interestingly, the repertoires of the SF
and PB Tregs showed the greatest frequency of clone sharing
(mean of 12.7% of SF Treg clones shared with PB Tregs, n = 4).
When the whole repertoire size was taken into account (not just
unique sequences but their relative abundance between two popu-
lations), the overlap of PB and SF Tregs was found to be almost 0.2,
and only a small overlap of SF Tregs and SF Tcons was found,
suggesting that SF Treg cluster most strongly by cell lineage (Treg)
and only weakly by anatomical site (SF) (Fig. 1D).
Tregs occupy a discrete TCR niche from effector T cells at the
inflamed site regardless of FOXP3 expression patterns
We have recently reported that the Treg signature in SF is atypical,
and that CD127 and CD25 expression are not sufficient to identify
the entire Treg footprint in SF due to the fact that CD25 and FOXP3
expression are frequently dissociated (6). We therefore explored
the relationships and origins of these atypical Treg populations at
the inflamed site. To do this, SFMCs were stained for CD4, CD25,
and CD127, then fixed and stained for FOXP3, before sorting into
their respective populations: P1: CD252FOXP3+, P2: CD25+
FOXP3+, P3: CD25+FOXP32, and Tcon: CD127hiCD252FOXP32
(Fig. 2A). Genomic DNAwas extracted and run on the immunoSEQ
human TCRB platform. Summary of the sequence reads obtained
from genomic DNA extracted from fixed human T cells is shown
in Table I. Clonality was slightly increased in Treg populations
compared with Tcons but was comparable with the findings
achieved with unfixed cells in Fig. 1B (Fig. 2B). The overlap at the
nucleotide level was then interrogated between the repertoires of
the four populations (Fig. 2C, 2E). The repertoires were first vi-
sualized in graphical form based on the frequency of a given clone
in each repertoire. This permitted correlation by Pearson’s coef-
ficient for the sharing of clones between two repertoires (Fig. 2C).
As can be seen in patient 5, clone sharing and correlations were
very weak between all three Treg repertoires and Tcons, but the
repertoires of each Treg associated strongly with each other, with
the strongest correlation between P2 and P3 (r2 = 0.646). These
data are summarized in Venn diagram form for two JIA patients
(Fig. 2D), revealing that typically between 20 and 50% of unique
TCR clones were shared between Treg populations, but only 2 and
7% with the SF Tcon, of which P3 Tregs showed the most overlap.
When total repertoire overlap was analyzed, taking into account
the frequency of the TCRB reads shared, the strong clustering of
the Treg repertories was strikingly apparent, with, on average,
.0.5 repertoire overlap between the Treg populations (Fig. 2E). In
fitting with the results in Fig. 1, repertoire overlap between P1
(mean = 0.064) and P2 (mean = 0.044) Tregs was minimal with
Tcons, again highlighting the near exclusivity of the Treg and
Tcon repertoires at the inflamed site. P3 Tregs showed some
overlap with Tcons (0.155), which could possibly reflect Tcon
contaminants within this population or possibly represent Tregs
that have converted to Tcons in vivo. The divergence of Tcon and
Treg repertoires is strikingly illustrated when the 30 most abun-
dant clones within patient 1 are analyzed (see Supplemental
Table II). As can be seen, 16 of 20 of the most abundant 20
clones were exclusive to the P1, P2, and P3 repertoires. Together,
these results strongly suggest that Treg clones are expanded at the
inflamed site, but that their expression patterns of CD25 and
FOXP3 are in flux.
A subpopulation of synovial Tregs exhibits unstable FOXP3
protein expression in vitro
We hypothesized that the expansion of Treg clones within the
confined joint environment would likely lead to intraclonal com-
petition for resources such as MHC and/or FOXP3/CD25 main-
tenance signals, for example, IL-2, with the result being that some
clones may downregulate expression of FOXP3 and/or CD25
in vivo. We hypothesized that instability in FOXP3 expression
would be revealed by in vitro culture of SF Tregs. To investigate
this, we isolated Tregs from SF, or the blood of healthy control
subjects and JIA patients, based on CD127 and CD25 expression
(Fig. 3A) and cultured them overnight; the expression of FOXP3
and CD25 was analyzed at T = 0, 4, and 20 h. Within the SF Tregs,
a FOXP3lo population was observed at 4 h, which was FOXP32
by 20 h. This was not as apparent in healthy control Tregs or JIA
PB Tregs. This was a highly reproducible finding, with a signifi-
cant downregulation in FOXP3 protein at both 4- and 20-h time
points (Fig. 3B). Interestingly, although FOXP3 mRNA levels
were lower at 4 h in SF Tregs compared with controls, this was not
true at T = 0 or T = 20 h, suggesting that FOXP3 downregulation
was largely due to protein loss, rather than transcriptional down-
regulation. Furthermore, addition of cycloheximide resulted in
downregulation of FOXP3 protein in control Tregs, but not SF
Tregs, suggesting that FOXP3 protein is rapidly lost in some SF
Tregs (Supplemental Fig. 2). Importantly, this protein loss was not
due to blockade of the Ab recognition site, because similar results
were obtained with either the 236A/E7 or PCH101 anti-FOXP3
clones, which are raised against different epitopes (data not shown).
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FOXP3 downregulation was not explained by apoptosis, because the
majority of the FOXP3lo compartment was negative for active caspase
3 at various time points during the culture (Fig. 3D).
Addition of SF, but not common g-chain cytokines, stabilizes
Treg FOXP3 protein expression
IL-2 is a known transcriptional activator of FOXP3 expression in
Tregs. However, we previously reported that IL-2 alone was in-
sufficient to restore FOXP3 expression in CD25+FOXP3lo Tregs
isolated from SF (6). Similarly, we found that IL-2, at both early
and late time points (Fig. 4A), or IL-7 and IL-15 (Fig. 4B) could
not prevent formation of a FOXP3lo Treg population. Similarly,
the immunosuppressive cytokines IL-10 and TGF-b could not
rescue the phenotype (data not shown).
Given that the majority of Tregs in SF express FOXP3, we
hypothesized that a balance of factors at the inflamed site may be
important for optimal FOXP3 expression. To investigate the effect
of the local environment on SF Treg FOXP3 downregulation, we
made a pool of SF from JIA patients and then added them to
cultures at 0, 10, or 50% final concentration. As shown in Fig. 4,
addition of SF to the cultures had a significant effect on the fre-
quency of CD25+FOXP3+ Tregs [Fig. 4C, 4D; median frequencies
42.1% (0% SF), 55.5% (10% SF), and 67.8% (50% SF), respec-
tively] and positively changed the levels of FOXP3 protein
[Fig. 4D, right panel; median increase 39.1% (10% SF) and 92.4%
(50% SF) respectively]. FOXP3 mRNA was analyzed in parallel;
interestingly, no differences in transcriptional activity were de-
tected, once again inferring that loss of FOXP3 was principally
driven by degradation of the transcription factor (Fig. 4E). Im-
portantly, the effect of SF on FOXP3 expression was not related to
improved cellular viability, because addition of SF did not sig-
nificantly alter the frequency of live cells in the cultures [Fig. 4F;
median viable cells 67.8% (0% SF), 71.2% (10% SF), and 68.0%
(50% SF), respectively].
FIGURE 1. The TCR repertoires of Tregs and Tcons show high exclusivity in blood and SF of JIA patients. PBMCs and SFMCs taken at the same time
from JIA patients were enriched for CD4+ T cells and then stained for CD4, CD127, and CD25. (A) Left panels show CD25 versus CD127 staining before
sorting. Tregs (CD4+CD127loCD25hi) and Tcons (CD4+CD127hiCD25lo) were sorted from both anatomical compartments; sort purities based on CD127
and CD25 expression are shown in the middle panels. A small sample of sorted cells was stained for FOXP3 (right panels). Genomic DNAwas extracted
from purified T cells and analyzed using the immunoSEQ TCRB survey platform (Adaptive Biotechnologies). (B) Graphs depict the clonality (top panel)
and frequency of the most abundant clone (bottom panel) in the TCR repertoires of the four sorted subsets (n = 4 individual JIA patients). Bars represent
mean 6 SEM. Statistical testing by one-way ANOVA. *p, 0.05. (C) Venn diagrams depict the sharing of unique clones (at nucleotide level) between each
sorted T cell subset from one of the four JIA patients (see Supplemental Fig. 1 for patients 2–4). The percentage figure represents the percentage of
sequences shared as a total of that T cell compartments repertoire. Blue represents PB Treg, green represents PB Tcons, black represents SF Tcons, and red
represents SF Tregs. Shared unique sequences are depicted in gray. These data are representative of four individuals. (D) Bar graph displaying overlap (as
calculated in Materials and Methods) among the four T cell populations. n = 4. Data are representative of four JIA patients, the cells were sorted, and DNA
was extracted in three independent experiments but analyzed in two separate runs on the immunoSEQ platform. Tc, Tcon; Tr, Treg.
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SF is a potent STAT3 activator in Tregs
Given that SF appeared to promote FOXP3 expression, we next
investigated key signaling pathways engaged by soluble factors
within SF. SF is known to be enriched for both proinflammatory
(IL-6, IL-12, TNF-a, and IL-1b, which are the current targets of
biologics) and anti-inflammatory factors like IL-10 (20). Using the
Luminex platform, we determined that IL-6 and IL-10 were the
most consistently detected cytokines found within SF, and inter-
estingly, these were strongly positively correlated (Fig. 5A), im-
plying a degree of homeostatic regulation within the joint.
Both IL-6 and IL-10 are activators of the STAT3 pathway, which
is thought to negatively regulate Treg differentiation (22, 23). We
confirmed that our pool of SF was able to strongly activate STAT3
in Tregs (.200% increase; Fig. 5B), but only very weakly STAT5
(∼15–20% increase). Neutralization of IL-6 signaling using the
therapeutic mAb to the IL-6R TOC abrogated the ability of SF to
activate STAT3, indicating that IL-6 was the predominant STAT3-
activating cytokine.
IL-6R signaling by SF can positively regulate Treg phenotype
IL-6 can redirect the differentiation of Tregs into the Th17 lineage
in mice (24, 25) and is thought to do this through a STAT3-
dependent mechanism. Given that SF was a potent STAT3 acti-
vator, it was unexpected that SF could stabilize FOXP3 expression
in synovial Tregs. We hypothesized that neutralization of IL-6
signaling in SF may act to further stabilize FOXP3 expression
by removing STAT3 signals within the joint. Surprisingly, co-
treatment of SF with TOC resulted in a trend for a reduction in
FOXP3 expression, suggesting that IL-6 signaling does not neg-
atively regulate committed Treg FOXP3 expression. In fact, IL-6R
signaling acted as a positive regulator of CTLA-4 expression on
healthy Tregs (Fig. 6B), and blockade of IL-6R signaling within
SF resulted in a small but statistically significant reduction in
FIGURE 2. Tregs occupy a discrete TCR niche from Tcons at the inflamed site regardless of FOXP3 expression patterns. SFMCs from a JIA patient were
stained for CD4, CD127, CD25, and FOXP3. (A) Left graph depicts CD25 versus FOXP3 staining (gated on CD4+CD127lo T cells) in the presort pop-
ulation. Three Treg and one Tcon population were then sorted as shown: P1: CD4+CD127loCD25loFOXP3hi; P2: CD4+CD127loCD25hiFOXP3hi; P3: CD4+
CD127loCD25hiFOXP3lo; and Tcon: CD4+CD127hiCD25loFOXP3lo. Purities of the sorted population from patient 5 are shown. (B) Clonality scores were
calculated using the immunoSEQ analyzer software and are shown for the four populations (n = 2). Bars represent mean 6 SEM. (C) Graphs depict the
frequency of unique and shared clones between the different Treg and Tcon subsets. Unique clones are placed on the x- or y-axis and are coded as follows:
green, P1 Tregs; red, P2 Tregs; blue, P3 Tregs, black, Tcons; and shared clones are in gray. Correlation was calculated using Pearson’s correlation. Axis
numbers represent log (10) scale. (D) Venn diagrams depict the sharing of unique clones (at nucleotide level) among the four isolated T cell subsets in two
separate patients. The figure represents the percentage of unique clones shared between the two repertoires as a total of the unique clones found in that T
cell compartments repertoire. Green represents P1 Treg, red represents P2 Tregs, blue represents P3 Tregs, black represents Tcons, and shared unique
sequences are depicted in gray. (E) Heat map showing degree of repertoire overlap in two JIA patients. These data are from two independent experiments.
Table I. Sequencing depth summary for patient 5 (Fig. 2)
Sample Name Total Unique Productive Total
Productive
Unique
Out of Frame
Total Out of Frame Unique Has Stop Total Has Stop Unique
P1 Treg 874505 13530 690085 10634 176697 2680 7723 216
P2 Treg 891752 10822 723079 8449 162974 2197 5699 176
P3 Treg 778669 6287 630511 4893 143825 1309 4333 85
Tcon 552247 21268 442549 16884 100383 4021 9315 363
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healthy Treg FOXP3 expression (Fig. 6B, 6C). Interestingly
neutralization of TNF-a had no effect on either protein. Culture of
control Tregs with or without rIL-6 demonstrated that the small
increase in FOXP3 protein was likely transcriptionally driven, be-
cause mRNA levels of FOXP3were also slightly elevated (Fig. 6D).
These findings suggest that IL-6 can exert proregulatory properties
FIGURE 3. A subpopulation of synovial Tregs exhibits unstable FOXP3 protein expression in vitro. Tregs (CD4+CD127loCD25hi) and Tcons (CD4+
CD127hiCD25lo) were isolated from the blood of healthy control subjects and JIA patients, or SF of JIA patients. Tregs were cultured in media for the
indicated time points. (A) At times T = 0, T = 4, and T = 20 (for Tregs), cells were stained for CD25 and FOXP3 and analyzed by flow cytometry (A and B),
or RNA extracted and analyzed for expression of FOXP3 (C). (B) Graph summarizes FOXP3 protein levels calculated using the median fluorescence
intensity (MFI) at the indicated time points and normalized to time 0; control Tregs: n = 5 (s), JIA PB Tregs: n = 3 (3), JIA SF Tregs: n = 8 (n). ***p ,
0.001, ****p, 0.0001. (C) The FOXP3 expression levels relative to GAPDH in control (s, n = 3) or SF Tregs (n, n = 5) over the 20-h culture period. Bars
represent mean 6 SEM. Statistical analysis was performed by two-way ANOVA. *p , 0.05. (A and B) Data are representative of at least three independent
experiments. (D) SF Tregs were stained for active Caspase 3 and FOXP3 at the indicated culture time points and analyzed by flow cytometry. Data are
representative of at least three individuals in two independent experiments.
FIGURE 4. Addition of SF, but not common g-chain cytokines, stabilizes Treg FOXP3 protein expression. (A) SF Tregs (CD4+CD127loCD25hi) were
sorted and then cultured for 0, 4, or 18 h in the presence or absence of 100 U/ml rhIL-2 before analysis of CD25 and FOXP3 expression by flow cytometry.
Data are representative of at least three experiments. (B) SF Tregs (CD4+CD127loCD25hi) were sorted and then cultured for 0 or 18 h in the presence or
absence of 100 U/ml rhIL-2, 20 ng/ml IL-7, or 20 ng/ml IL-15 before analysis of CD25 and FOXP3 expression by flow cytometry. Data are representative of
two independent experiments. (C) SF Tregs were isolated and cultured for 4 h in the presence of medium alone, or medium supplemented with 10 or 50%
final concentration of SF obtained from JIA patients. Displayed are flow cytometry plots showing CD25 versus FOXP3 expression in the various cultures.
(D) Summary graph of (C) showing the percentage CD25+FOXP3+ live cells (left) or percentage change in FOXP3 median fluorescence intensity from
untreated Tregs (right) in six individual JIA patients. Data are representative of two independent experiments. (E) In parallel to protein analysis in (C), FOXP3
expression relative to ACTB was assessed by RT-PCR, n = 4. (F) The frequency of viable cells in the cultures from (C) was determined based on uptake of a
fixable Live/Dead dye. Bars represent the medians. Statistical analysis by Friedman test with Dunn multiple comparison (**p # 0.01). ns, not significant.
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at the inflamed site, as has been reported in the generation of reg-
ulatory B cells in mice (26), but that other unidentified factors exist
in SF that additionally promote Treg FOXP3 protein stability.
Discussion
In this study, we have used-high throughput TCR sequencing to
reveal the relationships between CD4+ T cell subsets in JIA pa-
tients and have demonstrated that the stability of human synovial
Treg FOXP3 expression is highly sensitive to the local environ-
ment. Although our data establish that FOXP3 protein expression
is susceptible to downregulation, intriguingly this did not appear
to be paralleled by a FOXP3 transcriptional downregulation. Such
uncoupling of FOXP3 protein expression from transcriptional
activities has been reported previously (27), and was explained by
the fact that FOXP3 can be targeted for degradation by the
ubiquitin/proteasome pathway (27, 28). Culture of SF Tregs with
cycloheximide did not appear to accelerate FOXP3 loss, sug-
gesting that FOXP3 protein is rapidly turned over. Although this
would be difficult to show using limited primary cells from the
inflamed site in humans, the kinetics of the loss of FOXP3 protein in
this report are consistent with these previously published findings.
Our results suggest, unlike in those previous studies, that ex-
posure to inflammatory signals (in our case, contained within SF)
may act to stabilize FOXP3 expression. These data strongly suggest
that signals within the inflamed joint act to promote FOXP3 protein
stability. The identity of the factor(s) and pathways responsible are
as yet unidentified, but we were able to rule out IL-6 and TNF-a as
significantly contributing to FOXP3 downregulation. Our finding
that IL-6 did not induce FOXP3 downregulation, in contrast with a
recent study (27), may also be explained by the source and pre-
conditioning of Tregs used. Indeed, the studies by van Loosdregt
et al. (27) and Chen et al. (28) used a Treg activation step with
anti-CD3 and anti-CD28 in the presence of IL-2 before exposure
to inflammatory cytokines. In addition, many of the studies were
performed on murine isolated Tregs or with in vitro differentiated
human Tregs, the TSDR methylation status and FOXP3 stability
of which are likely to be different from ex vivo synovial Tregs. It
is also known that IL-6 can activate STAT5 (29), which may ex-
plain how it can weakly positively modulate FOXP3 expression,
as observed in this study. Therefore, the differentiation and/or
activation state of Tregs may be important for dictating the sen-
sitivity to inflammatory signals. Our demonstration, however, that
Tregs phosphorylate STAT3 in response to both SF and IL-6
suggest no issue with IL-6 sensitivity. Furthermore, our data
suggest that the therapeutic mechanism of TOC is unlikely to
work through boosting Tregs, because IL-6 was shown to exert a
positive effect on CTLA-4 expression.
IL-2 is known to be a positive transcriptional regulator of FOXP3
expression (30), and the observation that IL-2 and other common
g-chain cytokines failed to restore FOXP3 expression adds weight
to our conclusion that degradation, not transcriptional downregu-
lation, was the major mechanism behind FOXP3 loss. This finding
should be of interest to those wishing to use Tregs as therapy for
autoimmune disorders. Although most studies designed to gen-
erate and expand Tregs in vitro for use in clinic have used epi-
genetic motifs, such as the TSDR, to validate Treg stability, this
does not consider the possibility that posttranslational mechanisms
may negatively impact on Tregs at inflamed sites. It is known that
FIGURE 5. SF is a potent STAT3 activator in Tregs. Sixty SFs from JIA patients were analyzed for IL-10 and IL-6 levels using the Luminex platform.
(A) IL-6 and IL-10 levels show a strong positive correlation (r = 0.8140, Spearman’s rank, n = 60, p, 0.0001). (B) Tregs were isolated from healthy control
subjects and stimulated either with medium alone (gray filled histograms) or 10% SF pool (gray line), 10% SF in the presence of 10 mg/ml TOC (gray
dashed), 40% SF (black line), 40% SF in the presence of 10 mg/ml TOC (black dashed) or 10 ng/ml IL-6 (black filled histograms) for 15 min before fixation
and staining for p-STAT3 or p-STAT5. Numbers indicate the median fluorescence intensity of p-STAT. Data are representative of two independent experiments.
FIGURE 6. IL-6R signaling by SF can positively regulate FOXP3 and
CTLA-4 expression. (A) Tregs were isolated from the SF of a JIA patient
and cultured for 0 (left flow cytometry plot) or 18 h (right plots) in the
presence of medium alone, 10% SF, or 10% SF in the presence of 10 mg/ml
anti–IL-6R (TOC). Cells were stained for CD25 and FOXP3 expression.
Numbers represent the median fluorescence intensity (MFI) of FOXP3
expression. Summary box and whiskers plot displays the FOXP3 MFI
under the various culture conditions at the 18-h time point. Bars represent
medians plus quartiles. Statistical analysis by Friedman test, with Dunn
multiple comparisons, n = 5. (B–D) Tregs from control blood were isolated
and cultured for 48 h either in media alone, 10% SF, 10% SF + 10 mg/ml
anti–IL-6R (TOC), or 10% SF + 10 mg/ml anti–TNF-a before analysis of
total CTLA-4 (B) or FOXP3 (C) protein expression. (D) Tregs were cul-
tured with or without 10 ng/ml IL-6 for 48 h before analysis of FOXP3
expression by flow cytometry (left panel) or quantitative PCR (right
panel). Bars represent mean 6 SEM. Statistical analysis by repeated-
measures ANOVA, with Tukey’s multiple comparisons test (n = 3, *p ,
0.05, **p # 0.01, ***p = 0.001). All data are representative of at least
three independent experiments.
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cyclin-dependent kinase 2 can regulate the stability of FOXP3
protein (31), raising the possibility that factors affecting cell cycle/
division may also affect FOXP3 stability. As such, delineating the
signals responsible for stabilizing FOXP3 could open up new
avenues for therapeutic intervention. In particular, degradation of
FOXP3 may be the desired goal in tumor biology, to allow the
propagation of antitumor responses, as has been demonstrated
with anti-CTLA4 therapies (32). In contrast, stabilizing FOXP3
may be important for resolving chronic inflammation, as has been
demonstrated in a colitis model (27). Therefore, a detailed in-
vestigation of the signaling pathways engaged by exposure to,
and/or withdrawal from, SF would help to determine the mecha-
nisms at play.
Although the Treg community has taken as a rule of thumb that
stable FOXP3 expression is essential to Treg lineage stability, our
data investigating the TCR repertoires in human arthritis suggest a
more nuanced situation. It is strikingly apparent that there is limited
overlap between the Tcon and Treg repertoires, whether it is in
blood or at the inflamed site. This was also largely true for the
repertoires of atypical Treg populations CD252FOXP3+ and
CD25+FOXP32 with Tcons. This suggests that FOXP3 or CD25
downregulation does not necessarily lead to reprogramming of
Tregs; moreover, it suggests a dynamic picture where expanding
Treg clones likely compete for limited resources, which may lead
to fluctuations in FOXP3 and CD25 expression. In this study, we
must also consider the possibility that CD25+FOXP32 T cells
could also upregulate FOXP3+, that is, that FOXP3 levels can
both rise and fall within a given antigenic niche, possibly as a
result of competition for limited resources. This interpretation
would be in keeping with a recently proposed feedback control
perspective model for Tregs/FOXP3, which places more emphasis
on the function of FOXP3 as a negative feedback component of
T cell activation, rather than on its role in determining a distinct
T cell lineage (33).
Although FOXP3 loss has always been considered to be in-
dicative of Treg destabilization, the dynamics of FOXP3 expression
in individual cells is poorly understood. Evidence for a stable Treg
lineage has been published in mice, where the use of genetic re-
porter systems have shown that the majority of the Treg subset is
stable (34), and that any apparent conversion is a result of pro-
miscuous FOXP3 expression by conventional T cells, rather than
reprogramming of Tregs (35). The data presented in this article
can now start to address this situation in humans. Given that the
synovial Treg repertoire most closely aligns with blood Tregs,
rather than any other population, and that Treg and Tcon reper-
toires are near exclusive in blood and SF, our data give some
weight to a (largely) stable Treg lineage model. Similar recent
findings between Tregs and Tcons have also been reported in
human inflammatory bowel diseases, where minimal Treg and
Tcon repertoire overlap was observed (21), suggesting that the
Treg/Tcon repertoire divergence extends beyond blood and SF in
humans. This lineage divergence in itself does not preclude the
existence of hybrid Treg/Tcon phenotypes, the likes of which have
been observed in mouse (36), as well as within memory (37) and
CD161-expressing Tregs in humans (38, 39), because such cells
have been shown to retain their Treg functions.
Further exploratory research into the repertoire of Tregs in the
thymus compared with other tissues would help to ascertain the
validity of the Treg lineage model in humans. It remains contro-
versial how Tregs are selected in the thymus, with some evidence to
suggest that TCRs with high affinity for self-Ag are positively
selected into the Treg lineage (40); however, a recent study has
challenged this view and suggested that the same self-peptide can
select Tcons or Tregs with identical TCRs, but that the affinity of
the interaction determined whether the Treg and Tcon repertoires
were similar or different, implicating negative selection as an
important player (41). Clearly such in vivo studies in humans are
not feasible, but it would be highly informative to interrogate the
thymic repertoires in different T cell subsets, in particular, Tregs
and Tcons, to validate whether the repertoires are also divergent
early in their differentiation.
In summary, we have demonstrated that in human autoimmune
arthritis the TCR repertoires of Tregs and Tcons show high ex-
clusivity, both in blood and at the inflamed site, suggesting that
regulatory-like T cells occupy discrete antigenic niches. The ex-
pansion of Treg clones, however, likely leads to interclonal and
intraclonal competition for positive regulators of CD25 and FOXP3
expression within SF, resulting in some Tregs downregulating these
proteins. Given FOXP3’s central role in Treg biology, the future
identification of the signaling molecule(s) in SF that stabilizes
FOXP3 protein is likely to be of high therapeutic interest.
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